Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 56.7%, EPS fell 670.0%, free cash flow grew 10.3% and total debt rose 10,940.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ORGO
Organogenesis (ORGO) EV/Sales
As of 16 October 2026, Organogenesis (ORGO) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from 0.0× (June 2019) to 7.9× (May 2021); the current reading is higher than 25% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | 70.06% |
| FY2024 | 0.6× | (47.46%) |
| FY2023 | 1.2× | 69.29% |
| FY2022 | 0.7× | (72.20%) |
| FY2021 | 2.4× | 2.14% |
| FY2020 | 2.4× | 28.56% |
| FY2019 | 1.9× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.6× | 38.80% |
| Mar 2026 | 0.4× | (56.77%) |
| Dec 2025 | 1.0× | (0.02%) |
| Sep 2025 | 1.0× | 11.53% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLVR Clever Leaves Holdings Inc. compare | −0.3× |
| BGM BGM Group Ltd. compare | −0.1× |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| ORGO Organogenesis | 0.2× |
| AKBA Akebia Therapeutics, Inc. compare | 0.3× |
| OGI Organigram Global Inc. compare | 0.6× |
| PROCF Sofgen Pharma S.A compare | 0.7× |
| DERM Journey Medical Corporation compare | 2.0× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 2.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)